Novo Biosciences is currently in a Series A round to raise USD 5-10m for MSI-1436, a molecule that has the potential to regenerate human tissue following a heart attack, said CEO Kevin Strange.
Scientists at the MDI Biological Laboratory and Novo Biosciences have identified a drug candidate to restore heart muscle function following a heart attack. Their research on the role of MSI-1436 in regenerating heart muscle tissue in zebrafish and mice was described in a paper in the peer-reviewed journal “npj Regenerative Medicine.”
Scientists at the MDI Biological Laboratory and Novo Biosciences have identified a drug candidate to restore heart muscle function following a heart attack. Their research on the role of MSI-1436 in regenerating heart muscle tissue in zebrafish and mice was described in a paper in the peer-reviewed journal, npj Regenerative Medicine.
MDI Biological Laboratory in Mount Desert Island, Maine has been awarded a patent on a tiny molecule called MSI-1436.
This is a big deal for two reasons:
A new heart disease treatment successfully induced and accelerated regeneration of damaged tissue in zebrafish and mice. The U.S. Patent and Trademark Office is awarding a patent for the drug and further trials into its efficacy are planned.
The US Patent and Trademark Office recently announced they will grant a patent to MDI Biological Laboratory. The patent will allow the lab to use a molecule named MSI-1436, which could be used to stimulate the regeneration and repair of heart tissue.
A federal patent has been awarded to scientists from the MDI Biological Laboratory, a step that will allow research to proceed on a molecule that shows promise in helping heart tissue regenerate after a heart attack.
Three scientists at the Bar Harbor-based MDI Biological Laboratory have been awarded a patent — the first for the lab — for MSI-1436, a potential new heart disease drug that stimulates the repair and regeneration of heart tissue damaged by injuries like a heart attack.